Two infusions given 2 weeks apart
One infusion every 6 months thereafter
Each session lasts approximately 2.5 to 3.5 hours
atients are observed before, during, and after the infusion for safety and comfort
Ocrevus (ocrelizumab) is an FDA-approved infusion therapy for Multiple Sclerosis (MS), including relapsing forms (RMS) and primary progressive MS (PPMS). It targets overactive B cells in the immune system that damage nerves, helping to slow disease progression and reduce relapses.
Ocrevus may be recommended for patients who:
Eligibility is determined after reviewing your medical history with your neurologist.
Each session typically lasts 2.5 to 3.5 hours, including observation time.

Designed and developed by NOA Firm